Algernon Pharmaceuticals Inc. (AGNPF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Algernon Pharmaceuticals Inc. (AGNPF) with AI Score 42/100 (Weak). Algernon Health Inc. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Algernon Pharmaceuticals Inc. (AGNPF) Healthcare & Pipeline Overview
Algernon Health Inc., a clinical-stage biotech firm, focuses on developing treatments for liver, kidney, and neurological conditions. With a pipeline including repirinast and N,N-Dimethyltryptamine, the company targets unmet needs in non-alcoholic steatohepatitis, chronic kidney disease, and stroke, operating primarily in Canada and Australia.
Investment Thesis
Algernon Health Inc. presents a high-risk, high-reward investment opportunity typical of clinical-stage biotechnology companies. The primary value driver is the successful development and commercialization of its drug candidates, particularly repirinast for chronic kidney disease and N,N-Dimethyltryptamine for stroke and traumatic brain injuries. Positive clinical trial results and regulatory approvals are critical catalysts. With a market capitalization of $0.00B and a negative P/E ratio of -0.72, the company's valuation is highly dependent on future clinical and regulatory milestones. Key risks include clinical trial failures, regulatory hurdles, and the need for additional funding. Investors should carefully consider the speculative nature of this investment.
Based on FMP financials and quantitative analysis
Key Highlights
- Algernon Health Inc. operates as a clinical stage pharmaceutical development company.
- The company focuses on developing therapeutic drugs for non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke.
- Key pipeline drugs include repirinast for the treatment of chronic kidney disease.
- Another key pipeline drug is N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries.
- The company rebranded from Algernon Pharmaceuticals Inc. to Algernon Health Inc. in October 2025.
Competitors & Peers
Strengths
- Focus on unmet medical needs in large and growing markets.
- Proprietary drug candidates with patent protection.
- Experienced management team with expertise in drug development.
- Operations in Canada and Australia.
Weaknesses
- Clinical-stage company with no approved products.
- High dependence on clinical trial outcomes and regulatory approvals.
- Limited financial resources.
- Small market capitalization.
Catalysts
- Upcoming: Announcement of results from ongoing clinical trials for repirinast in chronic kidney disease.
- Upcoming: Initiation of clinical trials for N,N-Dimethyltryptamine in stroke patients.
- Upcoming: Potential regulatory approvals for its drug candidates in Canada and Australia.
- Ongoing: Progress in securing strategic partnerships with larger pharmaceutical companies.
- Ongoing: Advancements in drug delivery systems to improve efficacy and safety.
Risks
- Potential: Clinical trial failures for its drug candidates.
- Potential: Regulatory hurdles and delays in obtaining approvals.
- Potential: Competition from established pharmaceutical companies with greater resources.
- Ongoing: Need for additional funding to support its drug development programs.
- Ongoing: Dependence on key personnel and management team.
Growth Opportunities
- Expansion into New Therapeutic Areas: Algernon Health could explore expanding its drug development pipeline into related therapeutic areas, such as other forms of liver disease or neurological disorders. The market for novel therapeutics in these areas is substantial, with significant unmet medical needs. Successful expansion would require additional research and development investment, but could significantly increase the company's long-term growth potential. This could potentially add value in the next 3-5 years.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could accelerate the development and commercialization of Algernon Health's drug candidates. Collaborations can provide access to additional funding, expertise, and resources, increasing the likelihood of successful drug development. This could involve licensing agreements, joint ventures, or co-development partnerships. These partnerships could materialize within the next 1-2 years.
- Geographic Expansion: Expanding operations beyond Canada and Australia into other key markets, such as the United States or Europe, could significantly increase Algernon Health's revenue potential. These markets offer larger patient populations and higher drug prices. However, geographic expansion would require navigating complex regulatory frameworks and establishing local infrastructure. This expansion could begin in the next 2-3 years.
- Orphan Drug Designations: Pursuing orphan drug designations for its drug candidates could provide Algernon Health with significant regulatory and financial benefits, including market exclusivity and tax incentives. Orphan drug designations are granted for drugs that treat rare diseases or conditions. This strategy could accelerate the development and commercialization of its drugs for specific patient populations. The timeline for obtaining these designations is typically 1-2 years.
- Advancements in Drug Delivery Systems: Investing in advanced drug delivery systems could improve the efficacy and safety of Algernon Health's drug candidates. This could involve developing novel formulations or delivery methods that enhance drug absorption, reduce side effects, and improve patient compliance. This could provide a competitive advantage and increase the market potential of its drugs. This is an ongoing area of research and development with potential benefits within the next 3-5 years.
Opportunities
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Orphan drug designations for its drug candidates.
- Advancements in drug delivery systems.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Need for additional funding.
Competitive Advantages
- Patent protection for its drug candidates.
- Proprietary formulations and drug delivery systems.
- Clinical trial data demonstrating the safety and efficacy of its drugs.
- Regulatory exclusivity for approved drugs.
About AGNPF
Algernon Health Inc., established in 2015 and headquartered in Vancouver, Canada, is a clinical-stage pharmaceutical development company. Originally named Algernon Pharmaceuticals Inc., the company rebranded in October 2025 to Algernon Health Inc., reflecting its refined focus on addressing critical unmet medical needs. The company operates in Canada and Australia, concentrating on developing therapeutic drugs for non-alcoholic steatohepatitis (NASH), liver disease, chronic kidney disease (CKD), and stroke. Algernon Health's pipeline features repirinast, currently under development for the treatment of chronic kidney disease. Additionally, the company is exploring the potential of N,N-Dimethyltryptamine (DMT) for treating strokes and traumatic brain injuries. By targeting these specific areas, Algernon Health aims to provide innovative solutions for conditions with limited existing treatment options. The company's strategic approach involves rigorous clinical trials and partnerships to advance its drug candidates through the development process, ultimately seeking regulatory approval and commercialization.
What They Do
- Develops therapeutic drugs for non-alcoholic steatohepatitis (NASH).
- Focuses on treatments for liver disease.
- Develops therapies for chronic kidney disease (CKD).
- Researches treatments for strokes and traumatic brain injuries.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approval for its drugs from health authorities in Canada, Australia, and other countries.
- Aims to commercialize its drugs through partnerships or direct sales.
Business Model
- Develops and patents novel therapeutic drugs.
- Conducts clinical trials to demonstrate the safety and efficacy of its drugs.
- Seeks regulatory approval from health authorities.
- Monetizes its drugs through licensing agreements or direct sales.
Industry Context
Algernon Health Inc. operates within the biotechnology sector, a segment characterized by high innovation, intense competition, and significant regulatory oversight. The market for treatments related to non-alcoholic steatohepatitis, chronic kidney disease, and stroke is substantial and growing, driven by aging populations and lifestyle-related diseases. Competition includes established pharmaceutical companies and other biotech firms such as AAGH and ADXS also developing therapies for similar indications. Success in this industry hinges on scientific innovation, clinical trial outcomes, and regulatory approvals.
Key Customers
- Patients suffering from non-alcoholic steatohepatitis (NASH).
- Patients with liver disease.
- Individuals with chronic kidney disease (CKD).
- Patients who have suffered a stroke or traumatic brain injury.
Financials
Chart & Info
Algernon Pharmaceuticals Inc. (AGNPF) stock price: Price data unavailable
Latest News
-
Dow finishes higher as markets cheer potential Strait of Hormuz reopening
Yahoo! Finance: AGNPF News · Mar 23, 2026
-
Algernon Health to open brain-focused PET scanning clinic in Florida
proactiveinvestors.com · Mar 23, 2026
-
Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building
globenewswire.com · Mar 23, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AGNPF.
Price Targets
Wall Street price target analysis for AGNPF.
MoonshotScore
What does this score mean?
The MoonshotScore rates AGNPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Dow finishes higher as markets cheer potential Strait of Hormuz reopening
Algernon Health to open brain-focused PET scanning clinic in Florida
Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building
AGNPF OTC Market Information
The OTCQB Venture Market is the middle tier of the over-the-counter (OTC) market for U.S. companies. It is designed for developing or emerging companies, primarily those that cannot yet qualify for listing on a national exchange like the NYSE or NASDAQ. OTCQB companies must meet certain financial reporting standards, undergo an annual verification process, and maintain a minimum bid price, offering more transparency than the lowest OTC tier (OTCQX is the highest tier).
- OTC Tier: OTCQB
- Disclosure Status: Current
- Limited liquidity compared to major exchanges.
- Less stringent listing requirements may indicate higher risk.
- Potential for wider bid-ask spreads and price volatility.
- Lower levels of regulatory oversight compared to listed companies.
- Information asymmetry due to less analyst coverage.
- Verify the company's financial statements and SEC filings.
- Review the company's business plan and growth strategy.
- Assess the company's management team and their track record.
- Evaluate the company's competitive landscape and market position.
- Understand the risks associated with the company's business and industry.
- Check for any legal or regulatory issues.
- Consult with a financial advisor.
- Current disclosure status indicates compliance with OTCQB reporting requirements.
- Company has been operating since 2015.
- Focus on pharmaceutical development in specific therapeutic areas.
- Company has a history of name changes, which can sometimes indicate strategic shifts or restructuring.
Common Questions About AGNPF
What does Algernon Health Inc. do?
Algernon Health Inc. is a clinical-stage pharmaceutical development company that focuses on developing therapeutic drugs for areas with significant unmet medical needs. Specifically, Algernon Health is working on treatments for non-alcoholic steatohepatitis (NASH), liver disease, chronic kidney disease (CKD), and stroke. The company's pipeline includes repirinast for CKD and N,N-Dimethyltryptamine for stroke and traumatic brain injuries. By focusing on these specific areas, Algernon Health aims to provide innovative solutions for conditions with limited existing treatment options.
What do analysts say about AGNPF stock?
As of 2026-03-15, formal analyst coverage of Algernon Health Inc. (AGNPF) may be limited due to its OTCQB listing and small market capitalization. Investors should conduct their own due diligence and consider the inherent risks associated with investing in clinical-stage biotechnology companies. Key valuation metrics to consider include the potential market size for its drug candidates, the probability of successful clinical trial outcomes, and the likelihood of regulatory approvals. The company's growth prospects depend on its ability to advance its drug pipeline and secure strategic partnerships.
What are the main risks for AGNPF?
Algernon Health Inc. faces several key risks inherent to clinical-stage biotechnology companies. Clinical trial failures represent a significant risk, as negative results could halt the development of its drug candidates. Regulatory hurdles and delays in obtaining approvals from health authorities could also impact the company's timeline and financial prospects. Competition from larger pharmaceutical companies with greater resources poses a threat. The company's need for additional funding to support its drug development programs could lead to dilution of existing shareholders. Dependence on key personnel and management team is another risk factor.
What are the key factors to evaluate for AGNPF?
Algernon Pharmaceuticals Inc. (AGNPF) currently holds an AI score of 42/100, indicating low score. Key strength: Focus on unmet medical needs in large and growing markets.. Primary risk to monitor: Potential: Clinical trial failures for its drug candidates.. This is not financial advice.
How frequently does AGNPF data refresh on this page?
AGNPF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AGNPF's recent stock price performance?
Recent price movement in Algernon Pharmaceuticals Inc. (AGNPF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on unmet medical needs in large and growing markets.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AGNPF overvalued or undervalued right now?
Determining whether Algernon Pharmaceuticals Inc. (AGNPF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AGNPF?
Before investing in Algernon Pharmaceuticals Inc. (AGNPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Investment in clinical-stage biotechnology companies is highly speculative.